Compare WINA & CERT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WINA | CERT |
|---|---|---|
| Founded | 1988 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Retail: Computer Software & Peripheral Equipment |
| Sector | Consumer Discretionary | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.5B |
| IPO Year | 1993 | 2020 |
| Metric | WINA | CERT |
|---|---|---|
| Price | $445.30 | $9.61 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $12.78 |
| AVG Volume (30 Days) | 84.9K | ★ 1.9M |
| Earning Date | 02-18-2026 | 02-25-2026 |
| Dividend Yield | ★ 2.60% | N/A |
| EPS Growth | ★ 2.56 | N/A |
| EPS | ★ 11.21 | 0.07 |
| Revenue | $84,517,400.00 | ★ $415,551,000.00 |
| Revenue This Year | $7.05 | $10.75 |
| Revenue Next Year | $3.60 | $6.32 |
| P/E Ratio | ★ $38.87 | $140.30 |
| Revenue Growth | 3.35 | ★ 11.47 |
| 52 Week Low | $295.79 | $8.03 |
| 52 Week High | $527.37 | $15.69 |
| Indicator | WINA | CERT |
|---|---|---|
| Relative Strength Index (RSI) | 58.54 | 57.91 |
| Support Level | $419.10 | $9.20 |
| Resistance Level | $459.99 | $9.64 |
| Average True Range (ATR) | 20.72 | 0.35 |
| MACD | 2.70 | 0.06 |
| Stochastic Oscillator | 77.49 | 79.01 |
Winmark Corp is a franchisor of value-oriented retail store concepts that buy, sell, and trade gently used merchandise. The company has one reportable segment including Franchising and one non-reportable segment Leasing. The franchising segment franchises value-oriented retail store that buys, sell, trade, and consign merchandise as well as provide strategic consulting services relating to franchising. The leasing segment includes middle-market equipment leasing business and small-ticket financing business. It generates a majority of its revenue from the Franchising segment.
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval and increase patient access to medicines. The company has its business presence in the Americas which is also it key revenue generating market, EMEA and Asia Pacific region.